Form 4: Acrivon COO's Stock Withholding for Tax
Insider Transaction Report
Acrivon Therapeutics' Chief Operating Officer, Eric Devroe, reported a disposition of 613 common shares for tax withholding purposes related to restricted stock unit vesting.
Summary
- Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, Inc. (ACRV), reported a transaction on August 14, 2025.
- The transaction involved the disposition of 613 shares of common stock.
- These shares were withheld by the company to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
- The shares were valued at $1.39 per share for tax purposes.
- Following this transaction, Eric Devroe directly beneficially owns 65,921 shares of common stock.
Sentiment
Score: 5
Explanation: Neutral. This is a routine compliance filing (Form 4) reporting a non-discretionary transaction (shares withheld for tax upon RSU vesting). It does not reflect positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Disposition of shares by Chief Operating Officer Eric Devroe to the company for mandatory tax withholding upon vesting of restricted stock units, a standard compensation-related transaction.
Stakeholder Impact
- Shareholders: Minimal direct impact as it's a routine tax-related transaction, not a discretionary sale or a significant change in ownership percentage.
- Employees: Reflects standard executive compensation practices involving restricted stock units.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date Power of Attorney was executed by Eric Devroe. |
| 08/14/2025 | Date of the reported transaction (shares withheld for tax). |
| 08/18/2025 | Date the Form 4 was signed by the Attorney-in-Fact. |
Recommendation
holdThis Form 4 reports a routine, non-discretionary disposition of shares by the Chief Operating Officer to cover tax obligations upon the vesting of restricted stock units. Such transactions are common and do not typically indicate a change in the company's fundamental outlook or warrant a shift in investment strategy. Therefore, a 'hold' recommendation is appropriate as this filing provides no new information to alter an existing investment thesis.
Keywords
Acrivon Therapeutics, ACRV, Form 4, Insider Transaction, Stock Withholding, Restricted Stock Units, Eric Devroe, Chief Operating Officer, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.